Knowledge Center
Article / Jul 27, 2015
Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma
Source:
Manufacturing Chemist, 27 July 2015
Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.
Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.
Related links
Also in the Knowledge Center
/ Dec 07, 2016
Optimization of Supercritical CO2 Assisted Spray Drying for the Production of Inhalable Composite Particles
Read more
Scientific Article
/ Dec 07, 2016
Breathing Simulators: One step closer to representative deposition profiles?
Read more
Scientific Article
/ Dec 07, 2016
Paddle over disk as a dissolution test for orally inhaled drugs: discriminating composite from carrier-based formulations
Read more
Scientific Article